Literature DB >> 16990394

Omalizumab for asthma.

David E Winchester, Ashok Jacob, Tom Murphy.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16990394     DOI: 10.1056/NEJMc061914

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

Review 1.  Off-Label Uses of Omalizumab.

Authors:  David El-Qutob
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

2.  Churg-Strauss syndrome occurring during omalizumab treatment.

Authors:  Muhammed Bekçibaşı; Sezgin Barutçu; Mustafa Kemal Çelen; Saim Dayan; Salih Hoşoğlu
Journal:  Eur J Rheumatol       Date:  2015-03-31

Review 3.  Difficult-to-control asthma management through the use of a specific protocol.

Authors:  Pedro Giavina-Bianchi; Marcelo Vivolo Aun; Carla Bisaccioni; Rosana Agondi; Jorge Kalil
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

4.  Update on optimal use of omalizumab in management of asthma.

Authors:  Girolamo Pelaia; Luca Gallelli; Teresa Renda; Pasquale Romeo; Maria Teresa Busceti; Rosa Daniela Grembiale; Rosario Maselli; Serafino Antonio Marsico; Alessandro Vatrella
Journal:  J Asthma Allergy       Date:  2011-06-13

Review 5.  Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness.

Authors:  Corrado Pelaia; Cecilia Calabrese; Rosa Terracciano; Francesco de Blasio; Alessandro Vatrella; Girolamo Pelaia
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.